Elesta's laser gains clearance as a general surgical tool, expanding its addressable market beyond dermatology.
Elesta's ECHOLASER X4 has cleared FDA 510(k) review under product code GEX, with a determination of substantial equivalence for general and plastic surgery applications. The clearance broadens the device's labeling beyond dermatology-only use, opening it to surgical centers and hospital-based practices.
The ECHOLASER platform uses a hybrid laser technology and has been used in Europe for years. The 510(k) pathway—rather than a more rigorous PMA—suggests Elesta positioned it against existing general surgical lasers rather than claiming novel mechanism. This matters for practices: the device can now be marketed to plastic surgeons and general surgeons in the US, not just dermatologists and aestheticians.
General surgery clearance opens the device to surgical centers and hospital-based practices.
For medspa owners, the competitive implication is modest. The clearance doesn't displace InMode, Cutera, or Sciton in the aesthetic laser space, but it signals another entrant willing to pursue the US market through predicate-based clearance.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
